3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression.

Invest New Drugs

Lab. de Imunologia Celular, Instituto de Biofísica Carlos Chagas Filho, CCS Bl G, UFRJ, Rio de Janeiro, RJ 21949-900, Brazil.

Published: February 2012

Chronic myeloid leukemia (CML) is a potentially fatal stem-cell cancer. P-glycoprotein (P-gp/ABCB1) activity has been described as a relevant factor in the chemotherapeutic failure and correlated to a poor prognosis in these malignancies. In the present study, we investigated the mechanism of the antineoplastic activity of 3β-acetyl tormentic acid (3ATA), a triterpene isolated from C. lyratiloba, on Lucena-1, an MDR leukemia cell line, that overexpressed P-gp/ABCB1. Results showing that this triterpene induced DNA-fragmentation, activation of caspase-3 and cytochrome c release indicated that its activity is mediated by the activation of the intrinsic pathway of apoptosis. Interestingly, this triterpene did not interfere with P-gp/ABCB1 expression or activity, indicating that induction of death is not mediated by any effect on this protein. Moreover, the results show that none of the others triterpenes from C. lyratiloba were able to modulate the activity of P-gp/ABCB1. Together these results suggest 3ATA and the other triterpenes as a promising material for the development of anti-neoplastic drugs for leukemia and other tumors independent of P-gp/ABCB1 activity or expression.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9524-1DOI Listing

Publication Analysis

Top Keywords

p-gp/abcb1 activity
12
3β-acetyl tormentic
8
tormentic acid
8
activity expression
8
activity
7
p-gp/abcb1
6
acid induces
4
induces apoptosis
4
apoptosis resistant
4
leukemia
4

Similar Publications

This review examines the role of the canine blood-brain barrier (BBB) in health and disease, focusing on the impact of the multidrug resistance (MDR) transporter P-glycoprotein (P-gp) encoded by the gene. The BBB is critical in maintaining central nervous system homeostasis and brain protection against xenobiotics and environmental drugs that may be circulating in the blood stream. We revise key anatomical, histological and functional aspects of the canine BBB and examine the role of the gene mutation in specific dog breeds that exhibit reduced P-gp activity and disrupted drug brain pharmacokinetics.

View Article and Find Full Text PDF

The emergence of multidrug resistance (MDR) in malignant tumors is one of the major threats encountered currently by many chemotherapeutic agents. Among the various mechanisms involved in drug resistance, P-glycoprotein (P-gp, ABCB1), a member of the ABC transporter family that significantly increases the efflux of various anticancer drugs from tumor cells, and the metabolic enzyme CYP1B1 are widely considered to be two critical targets for overcoming MDR. Unfortunately, no MDR modulator has been approved by the FDA to date.

View Article and Find Full Text PDF

The overexpression of P-glycoprotein (P-gp/ABCB1) is a leading cause of multidrug resistance (MDR). Hence, it is crucial to discover effective pharmaceuticals that counteract ABCB1-mediated multidrug resistance. FRAX486 is a p21-activated kinase (PAK) inhibitor.

View Article and Find Full Text PDF

P-glycoprotein (P-gp, ABCB1) is a well-researched ATP-binding cassette (ABC) drug efflux transporter linked to the development of cancer multidrug resistance (MDR). Despite extensive studies, approved therapies to safely inhibit P-gp in clinical settings are lacking, necessitating innovative strategies beyond conventional inhibitors or antibodies to reverse MDR. Photodynamic therapy is a globally approved cancer treatment that uses targeted, harmless red light to activate non-toxic photosensitizers, confining its cytotoxic photochemical effects to disease sites while sparing healthy tissues.

View Article and Find Full Text PDF

P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) multidrug resistance (MDR) transporters are localized at the luminal surface of the blood-brain barrier (BBB). They confer fetal brain protection against harmful compounds that may be circulating in the peripheral blood. The fetus develops in low oxygen levels; however, some obstetric pathologies such as pre-eclampsia, placenta accreta/previa may result in even greater fetal hypoxic states.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!